Patients with phenotype D had significantly higher total CAT score than patients with other clinical phenotypes. Other than sleep quality, patients with phenotype D had significantly higher score in every other components, notably cough severity, phlegm volume, chest tightness, breathlessness upon walking uphill, activity limitation at home, ability to leave home and energy. There was no different in terms of total and components CAT score of patients with phenotype A, B and C. Background and Aims: The blood eosinophil count in patients with COPD exacerbation is reported to be associated with response to therapy, and it is also reported that patients with a severe eosinophilic COPD exacerbation have a shorter length of hospitalization. However, there is no report about the change in blood eosinophil count during the course of COPD exacerbation and its significance. So we examined the utility of blood eosinophil count before and after COPD exacerbation in predicting future exacerbation risk.
Conclusion
Methods: We retrospectively investigated consecutive hospitalized patients due to COPD exacerbation at Iizuka Hospital between December 2012 and December 2017. Inclusion criteria were as follows: Patients who underwent the following blood eosinophil count tests: at stable state before and after the admission, and chest computed tomography (on admission); Patients who have continued visiting our institution after the discharge. Thr following data were extracted from medical records: age, sex, BMI, pulmonary function tests (FEV1%predicted), severity of emphysema (Goddard classification), blood eosinophil count [at stable states before and after the admission (Eo-b and Eo-a, respectively)], frequency of COPD exacerbation, length of stay, and clinical course during and after admission.
Results: 130 patients were included. During the follow-up period (mean, 2.6 years), 77 patients did not experience COPD exacerbation (non-Ex group) and 53 patients experienced it more than once (Ex group). There was a statistically significant difference between the two groups in Eo-a (median, 242.1/μl in non-Ex vs 150.0/μl in Ex group; P = 0.002), not in Eo-b (205.0/μl vs 176.6/μl, P = 0.634).
Conclusion: Low blood eosinophil count at a stable state after COPD exacerbation may be one of the risk factors of future COPD exacerbation. A diagnosis of COPD is established by a post bronchodilator (BD) forced expiratory volume in the first second (FEV1)/forced vital capacity (FVC) ratio of less than 0.7 or the lower limit of normal (LLN). It is largely under diagnosed in developing countries for various reasons including lack of affordable spirometers in primary care settings. The peak expiratory flow
